Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Humacyte Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
HUMA
Nasdaq
8731
https://humacyte.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Humacyte Inc
Humacyte to Host Virtual KOL Event “Hemodialysis Access: A Crossroads of Care,” on March 28, 2024
- Mar 26th, 2024 8:05 pm
Humacyte, Inc. (NASDAQ:HUMA) Q4 2023 Earnings Call Transcript
- Mar 23rd, 2024 2:16 pm
Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update
- Mar 22nd, 2024 11:00 am
Humacyte to Present 2023 Fourth Quarter and Year-End Financial Results and Provide Corporate Update on March 22, 2024
- Mar 18th, 2024 12:00 pm
Humacyte, Inc. to Present at the TD Cowen 44th Annual Health Care Conference
- Mar 1st, 2024 2:16 pm
Humacyte, Inc. Announces Pricing of $40.2 Million Public Offering of Common Stock
- Mar 1st, 2024 2:18 am
Humacyte, Inc. Announces Proposed Public Offering of Common Stock
- Feb 29th, 2024 9:01 pm
Human Acellular Vessel™ (HAV™) Biologics License Application Granted Priority Review by U.S. FDA for the Treatment of Vascular Trauma
- Feb 9th, 2024 1:00 pm
Humacyte Submits Biologics License Application (BLA) to U.S. FDA Seeking Approval of Human Acellular Vessel™ (HAV™) for the Treatment of Vascular Trauma
- Dec 12th, 2023 1:00 pm
Humacyte to Present at the Piper Sandler 35th Annual Healthcare Conference
- Nov 24th, 2023 1:00 pm
Humacyte Announces Two Presentations at the VEITHsymposium® of Positive Clinical Results of the Human Acellular Vessel™ (HAV™) in the Treatment of Vascular Trauma
- Nov 17th, 2023 1:00 pm
Sidoti Events, LLC’s Virtual November Micro-Cap Conference
- Nov 14th, 2023 1:55 pm
Humacyte Third Quarter 2023 Financial Results and Business Update
- Nov 9th, 2023 9:01 pm
Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 9, 2023
- Nov 2nd, 2023 8:05 pm
Humacyte Publishes Preclinical Results Showing Human Acellular Vessel™ (HAV™) Patency as Modified Blalock–Taussig–Thomas Shunt in Juvenile Primate Model
- Oct 16th, 2023 12:55 pm
Several Insiders Invested In Humacyte Flagging Positive News
- Oct 2nd, 2023 3:37 pm
'Politicians have too much power': Sen. Tommy Tuberville recently disclosed $250K in agriculture futures — all while he's been influencing farming industry policies
- Sep 23rd, 2023 10:15 am
Humacyte to Present at the Cantor Global Healthcare Conference
- Sep 21st, 2023 8:05 pm
Humacyte to Host In-Person KOL Event at the New York EDITION on September 20, 2023
- Sep 18th, 2023 8:05 pm
Humacyte Announces Positive Top Line Results from Phase 2/3 Trial of Human Acellular Vessel™ (HAV™) in Treatment of Patients with Vascular Trauma
- Sep 12th, 2023 11:00 am
Scroll